We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tclarke Plc | LSE:CTO | London | Ordinary Share | GB0002015021 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 162.50 | 162.00 | 162.50 | 164.50 | 162.00 | 163.00 | 292,199 | 16:35:05 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Special Trade Contractor,nec | 491M | 6.5M | 0.1230 | 13.17 | 85.62M |
Date | Subject | Author | Discuss |
---|---|---|---|
30/3/2022 12:03 | Can anyone help me ? This site has CTO net debt at 122m. This appears not to include debtors, which is account receiveable which should be included in current assets which should be used to arrive at net debt. I was thinking of buying these but when I looked at market cap 65m and the size of net debt that threw me. However it looks fine if you include debtors. | yf23_1 | |
16/3/2022 09:28 | Quite a good write-up. But I can hardly believe the last line "my new target price of 170p.". Surely with the tailwinds and the 2022 EPS estimate of 21.2p and the great growth story this should be 200p or even more?? | edmundshaw | |
15/3/2022 13:16 | That’s odd I’ve had two say it worked but two that didn’t. I’ll pm you. If you have an iPhone try using that. | dr biotech | |
15/3/2022 13:00 | It didn't work for me I'm afraid Dr. B. I took the route you suggested but the same paywall... | edmundshaw | |
14/3/2022 16:45 | There’s an easy (legit) way round the IC paywall, just PM me.. | dr biotech | |
14/3/2022 14:31 | https://masterinvest | tole | |
12/3/2022 22:22 | Was behind a paywall for me :(( | edmundshaw | |
11/3/2022 15:59 | Positive write up in the IC. Its quite easy to access the article for free if anyone wants it. Decent article as always by Simon Thomson. | dr biotech | |
11/3/2022 15:12 | Excellent presentation, they seem a very focused management team with a clear vision. | igoe104 | |
11/3/2022 07:19 | Investor presentattion:- | cwa1 | |
10/3/2022 10:10 | Ah really, thanks. I was just assuming it was because people absorbed yesterday's results last night. | squarepeg86 | |
10/3/2022 09:46 | It was on the website last night, that's the reason for today's move. | gdjs100 | |
10/3/2022 09:33 | I wonder if this will feature in IC tomorrow, Simon Thompson seems to have T Clarke on his radar and likes to tip it. That generally brings the biggest rise here. | squarepeg86 | |
09/3/2022 18:15 | 09/03/2022 7:00am RNS Number : 0892E TClarke PLC Final Results | johnwise | |
09/3/2022 08:40 | Fall on net cash is of course just a consequence of the cash requirements of ongoing contracts. So in a sense it is a good thing! Anything under 150p seems stonking good value to me. Really consistent and safe growth stock at a value price. | edmundshaw | |
09/3/2022 08:05 | Funny, I was gonna post (roughly0 this: - "can anyone can find any negatives?" (struggling) ...I see you're all struggling too. Essentially I had forecasts as bang on track. Fall in net cash is all I could come up with FWIW. I would have to read the statement more thoroughly to assess the reasons on that, but VAT changes etc. I'd guess. | thorpematt | |
09/3/2022 07:50 | Couple of small pieces from this morning's Cenkos note:- We are not fundamentally changing our forward forecasts save for an upgrade to dividends, so after a 25% price correction YTD (All Share -8%) the shares represent outstanding value. TClarke trades on a FY23E EV/EBITDA of 2.5x (4x adjusted for pension deficit), PE of c5x, yield 4.5% with a FCF yield of 16% and an ungeared balance sheet. Buy. and Valuation: Until the recent market and particularly sector sell off, TClarke had been showing solid outperformance. The setback is a buying opportunity; given the group’s momentum an adjusted EV/EBITDA of 4x and PE of 5x with now accelerated dividend is highly attractive. | cwa1 | |
09/3/2022 07:39 | That seems reasonable 18BT. Off with their heads :-) | cwa1 | |
09/3/2022 07:37 | The only thing I can think of is that it is spot on the market forecast on all metrics except for the dividend, which it has beaten. So they could mark it down for not out performing the forecasts which the company guided them to... | 18bt | |
09/3/2022 07:34 | Not yet, I was looking for the same comma, but couldn't find it! Results look pretty good and the business seems to be heading in the right direction. A 17% increase in order book that comprises of a 188% increase in technology orders ensures a smoother runway and reduces the cyclicality of the business. IMHO DYOR | saurish | |
09/3/2022 07:20 | Looks good Has anyone found anything that the market can use as an excuse to mark this down? A COMMA MISSING OR SOMETHING LOL. Thats the current environment ! | john09 | |
08/3/2022 12:11 | I've had a bit of a wild swish and taken a few. Not expecting this to be the bottom, sadly I fear there's worse to come. However, fingers crossed it might be reasonable value longer term... | cwa1 | |
08/3/2022 11:30 | Looking forward to 07.00 tomorrow and Results :) | santangello | |
10/2/2022 13:42 | off she goes | albanyvillas | |
10/2/2022 13:16 | :) Yes especially when we can buy Perky on a Price Earnings ratio of 7 | albanyvillas |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions